Drug Trial Radar · NCT03693131
Efficacy of MND-2119 in Participants With Hypertriglyceridemia
Last checked: Nov 20, 2026Latest source record: Aug 1, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
580
Actual
Start
Oct 27, 2018
Primary completion
Jun 15, 2019
Study completion Jun 29, 2019
Sponsor
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of MND-2119 compared to EPADEL CAPSULES 300 in participants with hypertriglyceridemia.
Conditions
- Hypertriglyceridemia
Interventions
Icosapent (MND-2119)Drug
Icosapent (MND-2119) capsules.
Icosapent (EPADEL CAPSULES 300)Drug
Icosapent (EPADEL CAPSULES 300) capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of change from baseline in serum triglyceride level at 12 weeks after the start of study drug administrationTime frame: Baseline and 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mochida Investigational sites
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.